Abstract:This editorial will attempt to clarify concisely the current state of the field with regard to defining an EPC and challenge the ongoing use of the terms early and late EPC. The concept of a circulating human cell that could serve as a progenitor for the endothelial lineage was first proposed in 1997 [1]. Cell surface markers for hematopoietic and endothelial cells were used initially to identify the cells that displayed the ability to promote vascular endothelial repair following experimentally induced ischemic injury in vivo [1]. Subsequent investigations expanded the cell surface antigens that could be used to identify EPC, however none of the cell surface markers were found to be unique for or restricted to this circulating cell subset [2]. In vitro clonogenic assays were also developed to permit identification of EPC [2]. The colonyforming assays permitted identification of some circulating cells that failed to adhere initially to fibronectin-coated dishes for the first 48 h of plating but then became adherent to fibronectin and formed a colony of cells that emerged over the next 5–9 days (CFUHill). Other cells that adhered immediately to fibronectin-coated dishes and 4 days later (1) displayed distinctive changes in morphology, (2) demonstrated the ability to ingest Ac-LDL, and (3) bound the plant lectin Ulex europaeus were also defined as EPC (now called CACs; Fig. 1). The third assay used to identify emergence of adherent endothelial cobblestone-patterned colonies that appeared from 7 to 21 days after plating, were called ECFCs (Fig. 1). As the first two assays identified putative EPC within 4–9 days of plating, these cells were called early-outgrowth EPCs, whereas the ECFCs tended to emerge later in vitro and were referred to as late-outgrowth endothelial EPCs (Fig. 1). However, as noted above, the times of emergence of the colonies in the different assays were overlapping, and thus, the terminology was more confusing than discriminating [2]. The use of three different colony forming assays and numerous combinations of cell surface antigens to identify ostensibly the same EPC rapidly led to great controversy in the field. There appeared to be little correlation among these various identification methods when used simultaneously as biomarkers to attempt to stratify patients with different diseases into those with adequate vascular repair versus those with inadequate vascular repair. This lack of clarity on how to define an EPC significantly impacted and obscured the ability to translate the preclinical findings obtained in animal models into human clinical trials. In fact, many clinical trials were conducted with unfractionated autologous bone marrow cells as the selected test cell source and perhaps not too surprisingly, failed to demonstrate the same clinical impact predicted by the preclinical trial results. Over the past 15 years, great progress has been made in clarifying the specific cell types that were collectively referred to as EPCs initially. It should be pointed out that some of the selected cell surface markers first used to identify EPCs [1] included markers known to be coexpressed by HSPCs. For example, the “EPC” markers CD133, CD34, and VEGFR2 (kinase insert domain receptor) are known to (1) enrich human marrow cells for HSPCs, which can reconstitute multiple hematopoietic lineages upon transplantation into immunodeficient mice, (2) enrich for hematopoietic progenitor cells in methylcellulose colony assays, and (3) represent a cell population devoid of any ECFC [4]. Thus, the recent acknowledgment that much of the observed paracrine effects of the putative EPC on vascular repair are mediated by hematopoietic cells should not be surprising [5]. It has also now become clear that the CFU-Hill assay, used previously as an EPC assay, identifies proangiogenic myeloid progenitor cells and some lymphocyte cells (not a unique EPC), and the CAC assay identifies proangiogenic monocyte-derived macro-

Editorial: Early and late endothelial progenitor cells are miR‐tually exclusive

Acquiring and Identification of Endothelial Progenitor Cells from Human Peripheral Blood Mononuclear Cells by Sequential Adherence

Biological Properties of Endothelial Progenitor Cells Derived from Human Peripheral Blood Mononuclear Cells

Comparison of biological properties between human peripheral blood derived endothelial progenitor cells and mature vessel wall endothelial cells

In Vitro and in Vivo Angiogenic Capacity Analysis on Different Clonal Endothelial Progenitor Cell Populations Derived from Human Circulating Blood

Isolation and Cultivation of Different Clone Populations Derived from Human Peripheral Blood Mononuclear Cells for Differentiating into Endothelial Progenitor Cells

Comments to the Article "diverse Contribution of Bone Marrow-Derived Late-Outgrowth Endothelial Progenitor Cells to Vascular Repair under Pulmonary Arterial Hypertension and Arterial Neointimal Formation".

Differential expression of distinct surface markers in early endothelial progenitor cells and monocyte-derived macrophages.

Late Outgrowth Endothelial Cells Resemble Mature Endothelial Cells and Are Not Derived from Bone Marrow

Proteomic Analysis Reveals Presence of Platelet Microparticles in Endothelial Progenitor Cell Cultures.

Systematic assessment in an animal model of the angiogenic potential of different human cell sources for therapeutic revascularization

Putative Endothelial Progenitor Cells Derived from Chicken Bone Marrow Cells in Vitro: Effect of Basal Culture Media on their Morphological, Phenotypic and Functional Properties

Differential Characteristics and in Vitro Angiogenesis of Bone Marrow‐ and Peripheral Blood‐derived Endothelial Progenitor Cells: Evidence from Avian Species

[BIOLOGICAL FEATURES AND IDENTIFICATION OF ENDOTHELIAL PROGENITOR CELLS FROM PERIPHERAL BLOOD].

Endothelial Progenitor Cells in Angiogenesis.

Concise Review: Functional Definition of Endothelial Progenitor Cells: A Molecular Perspective

Comparison of the Biological Characteristics of Early and Late Endothelial Progenitor Cells Derived from Mouse Bone Marrow

Endothelial Progenitor Cells as Biomarkers of Cardiovascular Pathologies: A Narrative Review

Human Peripheral Blood-Derived Endothelial Colony-Forming Cells Are Highly Similar to Mature Vascular Endothelial Cells yet Demonstrate a Transitional Transcriptomic Signature

Pathogenesis of the worst killers of the 21st century

Origin, prospective identification, and function of circulating endothelial colony-forming cells in mice and humans